翻訳と辞書 Words near each other ・ "O" Is for Outlaw ・ "O"-Jung.Ban.Hap. ・ "Ode-to-Napoleon" hexachord ・ "Oh Yeah!" Live ・ "Our Contemporary" regional art exhibition (Leningrad, 1975) ・ "P" Is for Peril ・ "Pimpernel" Smith ・ "Polish death camp" controversy ・ "Pro knigi" ("About books") ・ "Prosopa" Greek Television Awards ・ "Pussy Cats" Starring the Walkmen ・ "Q" Is for Quarry ・ "R" Is for Ricochet ・ "R" The King (2016 film) ・ "Rags" Ragland ・ ! (album) ・ ! (disambiguation) ・ !! ・ !!! ・ !!! (album) ・ !!Destroy-Oh-Boy!! ・ !Action Pact! ・ !Arriba! La Pachanga ・ !Hero ・ !Hero (album) ・ !Kung language ・ !Oka Tokat ・ !PAUS3 ・ !T.O.O.H.! ・ !Women Art Revolution Dictionary Lists mini英和辞書 mini和英辞書 Webster 1913 Latin-English FOLDOC Wikipedia English ウィキペディア

翻訳と辞書　辞書検索 [ 開発暫定版 ] スポンサード リンク almorexant ： ウィキペディア英語版 almorexant Almorexant (INN, codenamed ACT-078573) is an orexin antagonist, functioning as a competitive receptor antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011.〔(GSK and Actelion discontinue clinical development of almorexant ) - GSK press release, 28 Jan 2011〕 ==Development== Originally developed by Actelion, from 2007 almorexant was being reported as a potential blockbuster drug, as its novel mechanism of action (orexin receptor antagonism) was thought to produce better quality sleep and fewer side effects than the traditional benzodiazepine and z drugs which dominated the multibillion-dollar insomnia medication market.〔(Sleeping Beautifully ) - CBS Business Network 24 Sep 2007〕〔(Is this FINALLY a cure for insomnia? The new pill which blocks the brain's 'stay awake' messages ) - Daily Mail, 28 July 2008〕 In 2008, pharmaceutical giant GlaxoSmithKline bought the development and marketing rights for almorexant from Actelion for an initial payment of $147 million.〔(Actelion Sells Glaxo Almorexant Sleep Medicine Rights ) - Bloomberg, 14 July 2008〕 The deal was worth a potential $3.2billion if the drug were to successfully complete clinical development and obtain FDA approval.〔(Actelion's top dollar deal leaves doubts, and little on the horizon ) - EP Vantage, 14 July 2008〕 GSK and Actelion continued to develop the drug together, and completed a Phase III clinical trial in November 2009.〔(Almorexant in Adult Subjects With Chronic Primary Insomnia (RESTORA 1). ) ClinicalTrials.gov (February 3, 2010). Retrieved on May 6, 2010.〕 However, in January 2011 Actelion and GSK announced they were abandoning the development of almorexant because of its side effect profile.〔〔(Actelion and GSK Discontinue Clinical Development of Almorexant ) - Actelion press release, 28 Jan 2011〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「almorexant」の詳細全文を読む スポンサード リンク 翻訳と辞書 : 翻訳のためのインターネットリソース Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.